b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="MEDLINE" Owner="NLM">\n        <PMID Version="1">31603362</PMID>\n        <DateCompleted>\n            <Year>2019</Year>\n            <Month>12</Month>\n            <Day>26</Day>\n        </DateCompleted>\n        <DateRevised>\n            <Year>2019</Year>\n            <Month>12</Month>\n            <Day>26</Day>\n        </DateRevised>\n        <Article PubModel="Print-Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">1744-7658</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>28</Volume>\n                    <Issue>12</Issue>\n                    <PubDate>\n                        <Year>2019</Year>\n                        <Month>Dec</Month>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Expert opinion on investigational drugs</Title>\n                <ISOAbbreviation>Expert Opin Investig Drugs</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Siponimod in the treatment of multiple sclerosis.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>1051-1057</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1080/13543784.2019.1676725</ELocationID>\n            <Abstract>\n                <AbstractText><b>Introduction</b>: Multiple sclerosis (MS) causes focal lesions of immune-mediated demyelinating events followed by slow progressive accumulation of disability. Over the past 2 decades, multiple medications have been studied and approved for use in MS. Most of these agents work by modulating or suppressing the peripheral immune system. Siponimod is a newer-generation sphingosine 1 phosphate (S1P) receptor modulator that internalizes S1P1 receptors, thereby inhibiting efflux of lymphocytes from lymph nodes and thymus. There are promising data suggesting that it may also have a direct neuroprotective property independent of peripheral lymphocytopenia.<b>Areas covered</b>: We reviewed the pharmacology and the clinical and radiological effects of siponimod.<b>Expert opinion</b>: The selective effect of siponimod on the S1P1 and S1P5 receptors offers a favorable side-effect profile and transient bradycardia can be avoided by dose titration. A phase-II study showed that siponomod has dose-dependent beneficial effects in patients with relapsing remitting disease. The results of a phase-III study suggest that siponimod may be beneficial in secondary progressive MS, at least in patients with disease activity.</AbstractText>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Goodman</LastName>\n                    <ForeName>Andrew D</ForeName>\n                    <Initials>AD</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Neuroimmunology Division, Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Anadani</LastName>\n                    <ForeName>Nidhiben</ForeName>\n                    <Initials>N</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Neurology, University of Oklahoma Medical Center, Oklahoma City, OK, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Gerwitz</LastName>\n                    <ForeName>Lee</ForeName>\n                    <Initials>L</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Neuroimmunology Division, Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n                <PublicationType UI="D016454">Review</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2019</Year>\n                <Month>11</Month>\n                <Day>03</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>England</Country>\n            <MedlineTA>Expert Opin Investig Drugs</MedlineTA>\n            <NlmUniqueID>9434197</NlmUniqueID>\n            <ISSNLinking>1354-3784</ISSNLinking>\n        </MedlineJournalInfo>\n        <ChemicalList>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D001384">Azetidines</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D001593">Benzyl Compounds</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D000081243">Sphingosine 1 Phosphate Receptor Modulators</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D000081025">Sphingosine-1-Phosphate Receptors</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>RR6P8L282I</RegistryNumber>\n                <NameOfSubstance UI="C578989">siponimod</NameOfSubstance>\n            </Chemical>\n        </ChemicalList>\n        <CitationSubset>IM</CitationSubset>\n        <MeshHeadingList>\n            <MeshHeading>\n                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D001384" MajorTopicYN="N">Azetidines</DescriptorName>\n                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>\n                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>\n                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D001593" MajorTopicYN="N">Benzyl Compounds</DescriptorName>\n                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>\n                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>\n                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D009103" MajorTopicYN="N">Multiple Sclerosis</DescriptorName>\n                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>\n                <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000081243" MajorTopicYN="N">Sphingosine 1 Phosphate Receptor Modulators</DescriptorName>\n                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>\n                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>\n                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000081025" MajorTopicYN="N">Sphingosine-1-Phosphate Receptors</DescriptorName>\n                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>\n                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>\n            </MeshHeading>\n        </MeshHeadingList>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="N">BAF-312</Keyword>\n            <Keyword MajorTopicYN="N">multiple sclerosis</Keyword>\n            <Keyword MajorTopicYN="N">progressive multiple sclerosis</Keyword>\n            <Keyword MajorTopicYN="N">siponimod</Keyword>\n            <Keyword MajorTopicYN="N">sphingosine 1 phosphate receptor</Keyword>\n        </KeywordList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2019</Year>\n                <Month>10</Month>\n                <Day>12</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2019</Year>\n                <Month>12</Month>\n                <Day>27</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2019</Year>\n                <Month>10</Month>\n                <Day>12</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">31603362</ArticleId>\n            <ArticleId IdType="doi">10.1080/13543784.2019.1676725</ArticleId>\n        </ArticleIdList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'